Phase 1b/2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer (VIRO-15)
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs GL ONC1 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms VIRO-15
- Sponsors Genelux Corporation
- 04 Aug 2017 The phase has been changed from 1b to 1b/2,with the addition of efficacy endpoint.Patient number also increases.
- 04 Aug 2017 Planned number of patients changed from 12 to 52.
- 04 Aug 2017 Planned End Date changed from 1 Sep 2018 to 1 Mar 2019.